Regional adjuvant irradiation for adenocarcinoma of the cecum.

Forty patients with adenocarcinoma of the cecum who underwent right hemicolectomy received regional irradiation for 40-45 Gy/4-5 weeks and weekly 5-Fluorouracil (5-FU). Thirty-four patients received this adjuvant therapy: 12, 10, 5, 4 with Stage B2, B3, C2, C3, respectively, and 3 with abdominal metastasis. Another six patients were similarly treated for palliation because of tumor bed recurrences.

Ovarian carcinoma: results of radiation therapy and chemotherapy in 83 patients.

Eighty-three patients with ovarian cancer who had undergone radiation therapy, chemotherapy, or both were evaluated. Eight patients had FIGO stage I, 12 had stage II, 61 had stage III, and two had stage IV disease. In 60 patients, radiation was delivered with open abdominopelvic field (30 Gy over 4 weeks), with or without a pelvic boost dose.

Split course pelvic irradiation and a boost for carcinoma of the prostate.

Fifty nine patients with prostatic cancer treated by definitive external irradiation were retrospectively evaluated. The true pelvis and prostate gland were irradiated by a split course technique for 48-50 Gy and 68-70 Gy in 7 weeks with a booster dose of 20 Gy delivered in the rest period (after 24-26 Gy) to the prostate via small ports. The overall 3 and 5 year actuarial survival was 83% and 75%, respectively.

Comparison of whole pelvis versus small-field radiation therapy for carcinoma of prostate.

One hundred thirty-six patients with adenocarcinoma of the prostate gland Stage A2 (12 patients), Stages B1 and B2 (26), Stage C (64), and Stages D1 and D2 (34 patients) were evaluated clinically and treated in a similar fashion at three hospitals. Megavoltage radiation therapy units were employed to deliver 4,600-5,000 cGy to the whole pelvis, and the prostatic area was treated for an additional 2,000 cGy (boost). Local recurrence was infrequent (8/136 = 6%), and the five-year actuarial survival and disease-free survival rates were 85 and 42 per cent, respectively.